Dr. Simona Lattanzi

Dr. Simona Lattanzi - latest findings of cenobamate used in real-life clinical practice

Professor Lattanzi is principal investigator in a recently published BLESS study (Read more about it below). We asked her about IEC, the congress themes that interest her the most and key take-aways from Angelini symposium. Watch the short interview below!

Cenobamate is a promising treatment option for adults with uncontrolled focal seizures, demonstrating significant seizure freedom rates in pivotal trials. Its efficacy was established in two studies, C013 and C017—randomized, double-blind, placebo-controlled trials enrolling 659 patients on 1–3 concomitant antiseizure medications (ASMs), with treatment durations of up to 18 weeks^1,2. Read more about C017 here.

While real-world evidence (RWE) from mainly highly refractory patient populations has corroborated the clinical trial result ^3-6. However, more studies are needed to assess cenobamate’s effectiveness when introduced earlier in the treatment journey.⁴ Ongoing and recently published^7,8 studies are addressing this gap, aiming to expand our understanding of cenobamate's clinical utility and its potential to improve patient outcomes. A a multicenter, retrospective and prospective BLESS study is one of the recently published studies that evaluates cenobamate in real-world clinical practice. Read more about it here.

Ontozry produktinformasjon

MAT-DK-0065-P 6.11.2025